This paper reports data from a nationwide audit of androgen deprivation therapy (ADT) and chemotherapy treatment for prostate cancer undertaken in New Zealand men within the first year after prostate cancer diagnosis. The study population included 15,947 men diagnosed with prostate cancer between 2006 and 2011; 4978 (31%) were prescribed ADT or chemotherapeutic agents. ADT was dispensed for 72% of men with metastatic disease, while only 24 men (0.2%) received chemotherapeutic agents. Age-adjusted analyses revealed that compared with younger men, older men (>70 years) with advanced (regional or metastatic) disease were more likely to receive anti-androgens only and to be treated with orchidectomy. Māori and Pacific men (compared with non-Māori/ non-Pacific men) were more likely to receive pharmacological ADT; Māori men were also more likely to be treated with orchidectomy
